Letters

Secondary prevention in coronary heart disease

BMJ 1999; 318 doi: http://dx.doi.org/10.1136/bmj.318.7195.1419 (Published 22 May 1999) Cite this as: BMJ 1999;318:1419

Effects of statins have been in addition to those of aspirin and

  1. Jonathan Morrell, Committee member, health care section of British Hyperlipidaemia Association
  1. Fitznells Manor Surgery, Ewell, Surrey KT17 1TF
  2. West Midlands Centre for Adverse Drug Reaction Reporting, City Hospital, Birmingham B18 7QH

    EDITOR—Ferner acknowledges the apparent similarity between the abilities of continuing aspirin and simvastatin to prevent “bad things.”1 He overlooks the fact that the positive outcomes of the secondary prevention statin studies were additional to the use of both aspirin and β blockers according to the investigators' cardiological practices at the time (table).24 Since the inception of the Scandinavian simvastatin survival study over a decade ago, subsequent trials have tested lipid modification with statins against a background of increasingly optimal practice, comfortably exceeding that described in the survey by Campbell et al.5

    View this table:

    Percentages of patients in each study who were taking aspirin …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe